Literature DB >> 2045303

Reduced incidence of bone metastases in irradiated areas after external radiation therapy of prostatic carcinoma.

H Jacobsson1, I Näslund.   

Abstract

Fourteen males, out of 380 patients, treated with radiation to the central pelvis and lumbar spine for poorly differentiated prostatic carcinoma were analyzed in retrospect. The dose of radiation to the bones of the target area was 5,000 cGy. The patients showed no signs of metastases at bone scintigraphy performed in connection with the treatment. In an average of 34 months after finishing radiotherapy, the patients developed metastases at bone scintigraphy. The pattern was similar in all patients. The treated target area appeared as a "cold zone" surrounded by more or less homogenously and strongly increased activity of the axial skeleton, characteristic of bone metastases. Radiography, which was performed in 11 patients, confirmed widespread metastatic disease sparing the target area. This was interpretated as bone metastasis being precluded by the irradiation. The most probable explanation of this finding is eradication in situ of distant micrometastases already present in the bone marrow at the time of treatment. An alternate explanation is a reduced implantation of later seeded blood-born metastases as an effect of the irradiation. The characteristic pattern of this phenomenon must be recognized at bone scintigraphy.

Entities:  

Mesh:

Year:  1991        PMID: 2045303     DOI: 10.1016/0360-3016(91)90241-u

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

1.  Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer.

Authors:  Mehmet Asim Bilen; Marcella M Johnson; Paul Mathew; Lance C Pagliaro; John C Araujo; Ana Aparicio; Paul G Corn; Nizar M Tannir; Franklin C Wong; Michael J Fisch; Christopher J Logothetis; Shi-Ming Tu
Journal:  Cancer       Date:  2014-08-22       Impact factor: 6.860

Review 2.  Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer.

Authors:  Shi-Ming Tu; Sue-Hwa Lin; Donald A Podoloff; Christopher J Logothetis
Journal:  Clin Adv Hematol Oncol       Date:  2010-05

3.  Prostate Cancer Old Problems and New Approaches. Part III. Prevention and Treatment.

Authors:  Kenneth V Honn; Amer Aref; Yong Q Chen; Michael L Cher; John D Crissman; Jeffrey D Forman; Xiang Gao; David Grignon; Maha Hussain; Arthur T Porter; J.Edson Pontes; Bruce Redman; Wael Sakr; Richard Severson; Dean G Tang; David P Wood
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

4.  Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer.

Authors:  Shi-Ming Tu; Paul Mathew; Franklin C Wong; Donnah Jones; Marcella M Johnson; Christopher J Logothetis
Journal:  J Clin Oncol       Date:  2009-05-04       Impact factor: 44.544

5.  Risk of metastasis among rib abnormalities on bone scans in breast cancer patients.

Authors:  Qin Li; Zhiqiang Chen; Yansheng Zhao; Xiuqing Li; Hong Pan; Tiansong Xia; Lin Chen; Zhaoqiang Xu; Wenbin Zhou; Xiaoan Liu
Journal:  Sci Rep       Date:  2015-05-05       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.